SCOTTSDALE, AZ--(Marketwire - Jan 6, 2012) - Arizona-based algae producer Health Enhancement Products (
Over the course of the last two years, Dahl has managed the Company's research and development efforts while repositioning the firm as a licensor of products derived from its proprietary algae cultures for the dietary supplement, food ingredient and medical food markets. He was also instrumental in developing a new business strategy and capital funding plan to attract new investment to the Company and continue to fund the R&D work underway at Battelle, one of the largest research organizations in the US.
Prior to forming Great Northern & Reserve Partners in 2005, Dahl served as marketing executive and consultant for over 20 years, working with Fortune 500 clients including Ford Motor Company, Northwest Airlines, General Motors, Xerox and Compuware, among others. As principal consultant at Great Northern & Reserve, he focused his efforts on biotech, biomed and emerging technology ventures. Dahl holds three US patents and named co-inventor on three biomed patent applications. He attended the College for Creative Studies and Wayne State University in Detroit, Michigan.
"We're pleased that Mr. Dahl was able to join this venture in a management capacity," says CFO Philip Rice. "His background, working knowledge of the product and his strategic approach to building product launch platforms will likely serve the Company and its shareholders well."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
Contact Information:
Contact:
IR
David Sasso
954-990-5451